PURPOSE: This study aims to analyze the clinical outcomes after isolated mitral valve (MV) repair in patients with reduced left ventricular ejection fraction (LVEF <50%) with focus on perioperative characteristics, survival, and freedom from reoperations. METHODS: Between 1997 and 2015, 557 patients with reduced LVEF (age: 62.8 ± 11.7 years, male: 320) underwent MV repair for symptomatic mitral regurgitation (MR). Etiologies were dilated non-ischemic cardiomyopathy and ischemic cardiomyopathy in 487 (87.4%) and 70 (12.6%) patients, respectively; these were classified into three different subgroups: LVEF 40%-49% (group 1), 30%-39% (group 2), and <30% (group 3). RESULTS: Overall, 294, 145, and 118 patients had an LVEF of 40%-49%, 30%-39%, and <30%, respectively. Logistic EuroSCORE was significantly higher (P <0.001) as the LVEF worsened. The survival analysis for groups 1-3, respectively, revealed the following: 30-day mortality: 1.4%, 3.4%, and 7.6% (P <0.001); 1-year survival: 93.9%, 89.4%, and 82% (P <0.001); 5-year survival: 81.2%, 75.2%, and 58% (P <0.001). CONCLUSION: MV repair in patients with impaired LVEF could be performed safely with good clinical short- and mid-term outcome. Nevertheless, reduced preoperative LVEF correlates with worse perioperative and long-term survival.
PURPOSE: This study aims to analyze the clinical outcomes after isolated mitral valve (MV) repair in patients with reduced left ventricular ejection fraction (LVEF <50%) with focus on perioperative characteristics, survival, and freedom from reoperations. METHODS: Between 1997 and 2015, 557 patients with reduced LVEF (age: 62.8 ± 11.7 years, male: 320) underwent MV repair for symptomatic mitral regurgitation (MR). Etiologies were dilated non-ischemic cardiomyopathy and ischemic cardiomyopathy in 487 (87.4%) and 70 (12.6%) patients, respectively; these were classified into three different subgroups: LVEF 40%-49% (group 1), 30%-39% (group 2), and <30% (group 3). RESULTS: Overall, 294, 145, and 118 patients had an LVEF of 40%-49%, 30%-39%, and <30%, respectively. Logistic EuroSCORE was significantly higher (P <0.001) as the LVEF worsened. The survival analysis for groups 1-3, respectively, revealed the following: 30-day mortality: 1.4%, 3.4%, and 7.6% (P <0.001); 1-year survival: 93.9%, 89.4%, and 82% (P <0.001); 5-year survival: 81.2%, 75.2%, and 58% (P <0.001). CONCLUSION: MV repair in patients with impaired LVEF could be performed safely with good clinical short- and mid-term outcome. Nevertheless, reduced preoperative LVEF correlates with worse perioperative and long-term survival.
Authors: Piroze M Davierwala; Joerg Seeburger; Bettina Pfannmueller; Jens Garbade; Martin Misfeld; Michael A Borger; Friedrich W Mohr Journal: Ann Cardiothorac Surg Date: 2013-11
Authors: Joerg Seeburger; Michael Andrew Borger; Volkmar Falk; Thomas Kuntze; Markus Czesla; Thomas Walther; Nicolas Doll; Friedrich Wilhelm Mohr Journal: Eur J Cardiothorac Surg Date: 2008-06-30 Impact factor: 4.191
Authors: Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano Journal: Eur Heart J Date: 2017-09-21 Impact factor: 29.983
Authors: Javed Butler; Gregg C Fonarow; Michael R Zile; Carolyn S Lam; Lothar Roessig; Erik B Schelbert; Sanjiv J Shah; Ali Ahmed; Robert O Bonow; John G F Cleland; Robert J Cody; Ovidiu Chioncel; Sean P Collins; Preston Dunnmon; Gerasimos Filippatos; Martin P Lefkowitz; Catherine N Marti; John J McMurray; Frank Misselwitz; Savina Nodari; Christopher O'Connor; Marc A Pfeffer; Burkert Pieske; Bertram Pitt; Giuseppe Rosano; Hani N Sabbah; Michele Senni; Scott D Solomon; Norman Stockbridge; John R Teerlink; Vasiliki V Georgiopoulou; Mihai Gheorghiade Journal: JACC Heart Fail Date: 2014-04 Impact factor: 12.035
Authors: Patrick T O'Gara; Paul A Grayburn; Vinay Badhwar; Luis C Afonso; John D Carroll; Sammy Elmariah; Aaron P Kithcart; Rick A Nishimura; Thomas J Ryan; Allan Schwartz; Lynne Warner Stevenson Journal: J Am Coll Cardiol Date: 2017-10-18 Impact factor: 24.094
Authors: Rakesh M Suri; Marie-Annick Clavel; Hartzell V Schaff; Hector I Michelena; Marianne Huebner; Rick A Nishimura; Maurice Enriquez-Sarano Journal: J Am Coll Cardiol Date: 2016-02-09 Impact factor: 24.094
Authors: Daniel Goldstein; Alan J Moskowitz; Annetine C Gelijns; Gorav Ailawadi; Michael K Parides; Louis P Perrault; Judy W Hung; Pierre Voisine; Francois Dagenais; A Marc Gillinov; Vinod Thourani; Michael Argenziano; James S Gammie; Michael Mack; Philippe Demers; Pavan Atluri; Eric A Rose; Karen O'Sullivan; Deborah L Williams; Emilia Bagiella; Robert E Michler; Richard D Weisel; Marissa A Miller; Nancy L Geller; Wendy C Taddei-Peters; Peter K Smith; Ellen Moquete; Jessica R Overbey; Irving L Kron; Patrick T O'Gara; Michael A Acker Journal: N Engl J Med Date: 2015-11-09 Impact factor: 91.245
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983